Casdin Capital LLC Grows Position in Denali Therapeutics Inc. $DNLI

Casdin Capital LLC boosted its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 106.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,840,000 shares of the company’s stock after purchasing an additional 950,000 shares during the quarter. Denali Therapeutics comprises about 1.9% of Casdin Capital LLC’s investment portfolio, making the stock its 12th largest position. Casdin Capital LLC’s holdings in Denali Therapeutics were worth $30,378,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in DNLI. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Denali Therapeutics by 4.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,507 shares of the company’s stock worth $1,210,000 after purchasing an additional 3,432 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Denali Therapeutics by 58.1% in the first quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company’s stock worth $22,732,000 after purchasing an additional 614,555 shares during the last quarter. Empowered Funds LLC grew its holdings in shares of Denali Therapeutics by 11.0% in the first quarter. Empowered Funds LLC now owns 20,639 shares of the company’s stock worth $281,000 after purchasing an additional 2,052 shares during the last quarter. Woodline Partners LP grew its holdings in Denali Therapeutics by 13.5% during the 1st quarter. Woodline Partners LP now owns 113,517 shares of the company’s stock worth $1,543,000 after acquiring an additional 13,517 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Denali Therapeutics by 1.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 191,613 shares of the company’s stock worth $2,681,000 after acquiring an additional 3,210 shares in the last quarter. 92.92% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on DNLI shares. Deutsche Bank Aktiengesellschaft set a $31.00 target price on shares of Denali Therapeutics in a report on Friday, May 22nd. BTIG Research reissued a “buy” rating and set a $39.00 price target on shares of Denali Therapeutics in a research report on Monday, May 11th. Wolfe Research initiated coverage on shares of Denali Therapeutics in a research report on Monday, February 23rd. They set a “peer perform” rating for the company. The Goldman Sachs Group increased their price target on shares of Denali Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Finally, HC Wainwright increased their price target on shares of Denali Therapeutics from $32.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $34.25.

Denali Therapeutics Price Performance

Shares of NASDAQ:DNLI opened at $23.49 on Thursday. The company’s 50 day moving average is $19.94 and its 200 day moving average is $19.52. Denali Therapeutics Inc. has a twelve month low of $12.58 and a twelve month high of $24.21. The company has a market cap of $3.73 billion, a PE ratio of -8.16 and a beta of 1.03. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04. During the same quarter last year, the firm posted ($0.78) earnings per share. On average, sell-side analysts forecast that Denali Therapeutics Inc. will post -2.77 EPS for the current year.

Denali Therapeutics Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.